Inflammatory marker analysis in psoriatic skin under topical phosphodiesterase 4 inhibitor treatment

J Allergy Clin Immunol. 2017 Oct;140(4):1184-1187.e8. doi: 10.1016/j.jaci.2017.04.026. Epub 2017 May 12.

Authors

Lennart M Roesner¹, Petra Kienlin², Gabriele Begemann², Oliver Dittrich-Breiholz³, Thomas Werfel²

Affiliations

¹ Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany. Electronic address: roesner.lennart@mh-hannover.de.
² Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
³ Research Core Unit Transcriptomics, Institute for Physiological Chemistry, Hannover Medical School, Hannover, Germany.

PMID: 28506848
DOI: 10.1016/j.jaci.2017.04.026

No abstract available

Publication types

Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Female
Gene Expression Regulation / drug effects
Humans
Male
Middle Aged
Phosphodiesterase 4 Inhibitors / therapeutic use*
Psoriasis / drug therapy*
Psoriasis / metabolism
Single-Blind Method
Skin / drug effects*
Skin / metabolism
Young Adult

Substances

Phosphodiesterase 4 Inhibitors